Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2024 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

The WHO urges governments to stand up to health-harming corporations  Editorial  In 2024, the World Health Organization (WHO) published a new landmark document that is both a review of the scientific literature and a political analysis, in the broad sense of the term, this time on the health-harming effects of the products and practices of certain sectors of industry (1-5). Full article available for download (free) 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ RSVPreF3/AS01E vaccine (Arexvy°) in the prevention of RSV infections from 60 years of age  Marketing Authorisations   The adjuvanted RSVPreF3/AS01E vaccine is the first vaccine authorised in the European Union for the prevention of RSV-associated lower respiratory tract infections in adults aged 60 years or older. Does it prevent respiratory infections in this population? Does it reduce hospitalisations and mortality? And what are its adverse effects? Full article available for download by subscribers (4 pages) 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Valoctocogene roxaparvovec (Roctavian°) in haemophilia A?  Marketing Authorisations   The gene therapy product valoctocogene roxaparvovec consists of a non-replicating adeno-associated virus serotype 5 (AAV5)-based vector that contains a DNA sequence encoding a variant of human factor VIII. It has been authorised in the European Union for the treatment of adults with severe haemophilia A on the basis of weak non-comparative data that suggest efficacy, but which declines over time. Full article available for download by subscribers 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Neuroleptics in patients with dementia: serious adverse effects  Adverse Effects   In 2024, a study using a British general practice database, linked to hospitalisation and mortality data, investigated several known adverse effects of neuroleptics in patients with dementia who were aged 50 years or older. Full article available for download by subscribers 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Dupilumab in severe asthma in children: helpful and without risk of infections or cancer?  Queries and Comments   Following the publication of Prescrire's analysis of evaluation data for dupilumab (Dupixent°) in severe asthma in children aged 6 years or older (Prescrire Int October 2023), members of Crisalis, an international clinical research network studying severe asthma, wrote to express their differing conclusions on dupilumab's benefits and harms in this situation. Full article available for download by subscribers (3 pages) 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Revision of European pharmaceutical legislation: an opportunity to transform the system of R&D incentives  Outlook   In the context of the ongoing revision of European pharmaceutical legislation, a report by the European Parliament's Panel for the Future of Science and Technology has set out options for major changes to Europe's pharmaceutical research and development (STOA) system. Here, Prescrire publishes excerpts from the report's insightful analyses providing clarifications in the form of editors' notes. Full article (4 pages) available for download (free) 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Too many scientific articles continue to be cited after their retraction  Outlook   About 60 out of 100 000 articles are retracted after publication. Unfortunately, those who read or cite them are not always aware of their retracted status.  Full article available for download (free) 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON•  Mavacamten in hypertrophic cardiomyopathy • Dostarlimab in endometrial cancer • VEGF inhibitors by intravitreal administration: systemic adverse effects • Drugs to avoid in 2025  > Subscribe now 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn, Facebook and X Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn, > Follow us on Facebook or > Follow us on X 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2024 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---